News | April 30, 2021
Lonza and Moderna enter new agreement to double drug substance production for COVID-19 vaccine
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
_256_384.jpeg)
Against the present demand from 20 states of 6,785 MT/day of Liquid Medical Oxygen, the Government of India has from 21st April allocated 6,822 MT/day to these states
The country has constantly worked with the spirit of public-private partnership
Essential medicines were made available to more than 150 countries around the world during the pandemic
Subscribe To Our Newsletter & Stay Updated
